CorMedix Inc.
CRMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.40 | -0.18 | 4.28 | 2.34 |
| FCF Yield | -10.64% | -20.24% | -14.51% | -13.19% |
| EV / EBITDA | -23.01 | -3.21 | -4.22 | -4.04 |
| Quality | ||||
| ROIC | -24.35% | -69.14% | -53.76% | -44.24% |
| Gross Margin | 92.66% | 0.00% | 94.29% | 22.00% |
| Cash Conversion Ratio | 2.82 | 0.83 | 0.82 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 772.69% | -100.00% | -35.10% | -12.32% |
| Free Cash Flow Growth | -30.96% | -57.62% | -8.84% | -2.27% |
| Safety | ||||
| Net Debt / EBITDA | 2.11 | 0.93 | 1.42 | 1.78 |
| Interest Coverage | -614.10 | 0.00 | -1,154.97 | -1,846.43 |
| Efficiency | ||||
| Inventory Turnover | 0.42 | 0.10 | 0.00 | 49.51 |
| Cash Conversion Cycle | 1,106.30 | -3,859.02 | -215,260.95 | -5,320.82 |